Tarceva Approval History
FDA Approved: Yes (First approved November 18, 2004)
Brand name: Tarceva
Generic name: erlotinib
Dosage form: Tablets
Treatment for: Non-Small Cell Lung Cancer, Pancreatic Cancer
Tarceva (erlotinib) is a kinase inhibitor indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Development History and FDA Approval Process for Tarceva
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.